Dalbavancin - A novel lipoglycopeptide antimicrobial for gram positive pathogens

Biswadeep Das, Chayna Sarkar, Rakesh Biswas, Sureshwar Pandey

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Glycopeptide antibiotics represent an important class of microbial compounds produced by several genera of actinomycetes. The emergence of resistance to glycopeptides among enterococci and staphylococci has prompted the search for second-generation drugs of this class and semi-synthetic derivatives are currently under clinical trials. Antimicrobial resistance among gram-positive organisms has been increasing steadily during the past several decades. Dalbavancin, a novel lipoglycopeptide, has a mechanism of action similar to that of other glycopeptides. It has in vitro activity against a variety of Gram-positive organisms specially multidrug resistant Staphylococcus aureus, but no activity against Gram-negative or vancomycin-resistant enterococci that possess vanA gene. Due to its prolonged half-life (6-10 days), dalbavancin can be administered intravenously once weekly. In Phase II and III clinical trials, dalbavancin was effective and well-tolerated for the treatment of skin and soft-tissue infections, catheter-related bloodstream infections, and skin and skin-structure infections. To date, adverse events have been mild and limited; the most common being pyrexia, headache, diarrhea. Dalbavancin appears to be a promising antimicrobial agent for the treatment of Gram-positive infections. Additional clinical data are required to fully assess its use. Despite the remarkable and favorable pharmacokinetic and pharmacodynamic properties, the use of this potent agent should be restricted to severe infections due to multidrug resistant organisms to limit the risk of selection of resistance. It is active against Gram-positive aerobes and anerobes, including resistant pathogens, with the exception of strains producing vanA-mediated resistance.. Its approval by the FDA is expected soon. The extent to which dalbavancin will supplant vancomycin and whether it will be preferred over other newer agents such as linezolid in the next decade remains to be seen.

Original languageEnglish
Pages (from-to)78-88
Number of pages11
JournalPakistan Journal of Pharmaceutical Sciences
Volume21
Issue number1
Publication statusPublished - 01-12-2008
Externally publishedYes

Fingerprint

Glycopeptides
Linezolid
Skin
Infection
Catheter-Related Infections
Phase III Clinical Trials
Phase II Clinical Trials
Soft Tissue Infections
Actinobacteria
Enterococcus
Vancomycin
Anti-Infective Agents
Staphylococcus
Headache
Half-Life
Staphylococcus aureus
Diarrhea
Fever
Pharmacokinetics
dalbavancin

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Das, Biswadeep ; Sarkar, Chayna ; Biswas, Rakesh ; Pandey, Sureshwar. / Dalbavancin - A novel lipoglycopeptide antimicrobial for gram positive pathogens. In: Pakistan Journal of Pharmaceutical Sciences. 2008 ; Vol. 21, No. 1. pp. 78-88.
@article{a6420927f9544ae8b83d3adcf5a6d41d,
title = "Dalbavancin - A novel lipoglycopeptide antimicrobial for gram positive pathogens",
abstract = "Glycopeptide antibiotics represent an important class of microbial compounds produced by several genera of actinomycetes. The emergence of resistance to glycopeptides among enterococci and staphylococci has prompted the search for second-generation drugs of this class and semi-synthetic derivatives are currently under clinical trials. Antimicrobial resistance among gram-positive organisms has been increasing steadily during the past several decades. Dalbavancin, a novel lipoglycopeptide, has a mechanism of action similar to that of other glycopeptides. It has in vitro activity against a variety of Gram-positive organisms specially multidrug resistant Staphylococcus aureus, but no activity against Gram-negative or vancomycin-resistant enterococci that possess vanA gene. Due to its prolonged half-life (6-10 days), dalbavancin can be administered intravenously once weekly. In Phase II and III clinical trials, dalbavancin was effective and well-tolerated for the treatment of skin and soft-tissue infections, catheter-related bloodstream infections, and skin and skin-structure infections. To date, adverse events have been mild and limited; the most common being pyrexia, headache, diarrhea. Dalbavancin appears to be a promising antimicrobial agent for the treatment of Gram-positive infections. Additional clinical data are required to fully assess its use. Despite the remarkable and favorable pharmacokinetic and pharmacodynamic properties, the use of this potent agent should be restricted to severe infections due to multidrug resistant organisms to limit the risk of selection of resistance. It is active against Gram-positive aerobes and anerobes, including resistant pathogens, with the exception of strains producing vanA-mediated resistance.. Its approval by the FDA is expected soon. The extent to which dalbavancin will supplant vancomycin and whether it will be preferred over other newer agents such as linezolid in the next decade remains to be seen.",
author = "Biswadeep Das and Chayna Sarkar and Rakesh Biswas and Sureshwar Pandey",
year = "2008",
month = "12",
day = "1",
language = "English",
volume = "21",
pages = "78--88",
journal = "Pakistan Journal of Pharmaceutical Sciences",
issn = "1011-601X",
publisher = "Pakistan Journal of Pharmaceutical Sciences",
number = "1",

}

Dalbavancin - A novel lipoglycopeptide antimicrobial for gram positive pathogens. / Das, Biswadeep; Sarkar, Chayna; Biswas, Rakesh; Pandey, Sureshwar.

In: Pakistan Journal of Pharmaceutical Sciences, Vol. 21, No. 1, 01.12.2008, p. 78-88.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Dalbavancin - A novel lipoglycopeptide antimicrobial for gram positive pathogens

AU - Das, Biswadeep

AU - Sarkar, Chayna

AU - Biswas, Rakesh

AU - Pandey, Sureshwar

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Glycopeptide antibiotics represent an important class of microbial compounds produced by several genera of actinomycetes. The emergence of resistance to glycopeptides among enterococci and staphylococci has prompted the search for second-generation drugs of this class and semi-synthetic derivatives are currently under clinical trials. Antimicrobial resistance among gram-positive organisms has been increasing steadily during the past several decades. Dalbavancin, a novel lipoglycopeptide, has a mechanism of action similar to that of other glycopeptides. It has in vitro activity against a variety of Gram-positive organisms specially multidrug resistant Staphylococcus aureus, but no activity against Gram-negative or vancomycin-resistant enterococci that possess vanA gene. Due to its prolonged half-life (6-10 days), dalbavancin can be administered intravenously once weekly. In Phase II and III clinical trials, dalbavancin was effective and well-tolerated for the treatment of skin and soft-tissue infections, catheter-related bloodstream infections, and skin and skin-structure infections. To date, adverse events have been mild and limited; the most common being pyrexia, headache, diarrhea. Dalbavancin appears to be a promising antimicrobial agent for the treatment of Gram-positive infections. Additional clinical data are required to fully assess its use. Despite the remarkable and favorable pharmacokinetic and pharmacodynamic properties, the use of this potent agent should be restricted to severe infections due to multidrug resistant organisms to limit the risk of selection of resistance. It is active against Gram-positive aerobes and anerobes, including resistant pathogens, with the exception of strains producing vanA-mediated resistance.. Its approval by the FDA is expected soon. The extent to which dalbavancin will supplant vancomycin and whether it will be preferred over other newer agents such as linezolid in the next decade remains to be seen.

AB - Glycopeptide antibiotics represent an important class of microbial compounds produced by several genera of actinomycetes. The emergence of resistance to glycopeptides among enterococci and staphylococci has prompted the search for second-generation drugs of this class and semi-synthetic derivatives are currently under clinical trials. Antimicrobial resistance among gram-positive organisms has been increasing steadily during the past several decades. Dalbavancin, a novel lipoglycopeptide, has a mechanism of action similar to that of other glycopeptides. It has in vitro activity against a variety of Gram-positive organisms specially multidrug resistant Staphylococcus aureus, but no activity against Gram-negative or vancomycin-resistant enterococci that possess vanA gene. Due to its prolonged half-life (6-10 days), dalbavancin can be administered intravenously once weekly. In Phase II and III clinical trials, dalbavancin was effective and well-tolerated for the treatment of skin and soft-tissue infections, catheter-related bloodstream infections, and skin and skin-structure infections. To date, adverse events have been mild and limited; the most common being pyrexia, headache, diarrhea. Dalbavancin appears to be a promising antimicrobial agent for the treatment of Gram-positive infections. Additional clinical data are required to fully assess its use. Despite the remarkable and favorable pharmacokinetic and pharmacodynamic properties, the use of this potent agent should be restricted to severe infections due to multidrug resistant organisms to limit the risk of selection of resistance. It is active against Gram-positive aerobes and anerobes, including resistant pathogens, with the exception of strains producing vanA-mediated resistance.. Its approval by the FDA is expected soon. The extent to which dalbavancin will supplant vancomycin and whether it will be preferred over other newer agents such as linezolid in the next decade remains to be seen.

UR - http://www.scopus.com/inward/record.url?scp=41649095277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41649095277&partnerID=8YFLogxK

M3 - Review article

VL - 21

SP - 78

EP - 88

JO - Pakistan Journal of Pharmaceutical Sciences

JF - Pakistan Journal of Pharmaceutical Sciences

SN - 1011-601X

IS - 1

ER -